logo
Plus   Neg
Share
Email

ObsEva Submits MAA To EMA For YSELTY For Treatment Of Women With Uterine Fibroids

ObsEva SA (OBSV) said that it has submitted a marketing authorization application to the European Medicines Agency or EMA for YSELTY or linzagolix 100mg and linzagolix 200mg for the management of heavy menstrual bleeding associated with uterine fibroids.

ObsEva expects that the EMA will notify the company in December 2020 regarding the outcome of its validation of the MAA to ensure all essential regulatory elements required for a scientific assessment are included in the application prior to the start of the procedure.

ObsEva expects to submit a new drug application to U.S. Food and Drug Administration in the first-half of 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
General Electric Co. filed a lawsuit against Siemens Energy AG, accusing the German power distribution company of stealing trade secrets for gas turbines. Siemens Energy allegedly used the information to get at least nine contracts to supply gas turbines to public utilities, and also covered up improper business gains. Following a court ruling, the U.S. Food and Drug Administration postponed the effective date for tobacco manufacturing companies to display new health warnings on cigarette packets and in advertisements, by additional 90 days. The warnings with color images is to promote greater public understanding of the negative health consequences of smoking. JPMorgan Chase & Co (JPM) reported strong results in the fourth quarter of 2020, with net profit up 42% largely driven by credit reserve releases of $2.9 billion. The Group said it ended the year with a CET1 ratio of 13.1% and capital above $200 billion, providing with meaningful capacity to further...
RELATED NEWS
Follow RTT